Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
49 hedge funds and large institutions have $220M invested in Alder Biopharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$45.1M |
| 2 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
+$35M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$11.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.8M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$10.4M |
Top Sellers
ALDR Hedge Fund Activity: Q2 2014 in Review
49 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q2 2014, worth a combined $220M.
Buyers outnumbered sellers: 49 funds opened new ALDR positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $45.1M.
- 49 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q2 2014, up from 0 in Q1 2014.
- Funds reported $220M of Alder Biopharmaceuticals stock for Q2 2014.
- 49 funds opened new Alder Biopharmaceuticals positions in Q2 2014 and 0 closed out, a net change of +49 holders.
- The largest Alder Biopharmaceuticals buyer in Q2 2014 was Novo Holdings A/S, an estimated $45.1M added.
Based on aggregated 13F filings for Q2 2014.